What are analysts' ratings for Erasca?
Analysts tracking Erasca, Inc. maintain a favorable consensus rating, reflecting institutional optimism surrounding its precision oncology pipeline targeting difficult-to-treat RAS/MAPK pathway-driven cancers. Financial research reports highlight promising early- and mid-stage clinical trial data for its selective inhibitors, a strengthened balance sheet following strategic capital raises, and collaborations with major pharmaceutical entities. While covering analysts acknowledge the high-risk, pre-commercial nature typical of clinical-stage biotechnology developers, consensus sentiment leans toward buy recommendations based on scientific potential.
Related FAQs
The long-term outlook for Erasca, Inc. (ERAS) is characterized by high volatility and heavy dependence on the success of its clinical pipeline.
Erasca, Inc. was officially founded in 2018 by a team of experienced oncology drug developers and life science entrepreneurs with a singular mission to erase cancer.
Erasca, Inc. is a clinical-stage oncology company that trades on the Nasdaq stock market under the ticker symbol ERAS.
Yes, Regencell Bioscience Holdings Limited (RGC) completed a 38-for-one forward stock split in June 2025. The company announced this split on June 2, 2025, and established a record date of June 12, 2025.
As of July 2026, Erasca, Inc. (ERAS) has a dividend yield of 0.00%. The company is a clinical-stage oncology firm that focuses on developing advanced treatments for cancer, and as such, it does not currently pay dividends to its shareholders.
Recent news concerning Erasca, Inc. has been dominated by legal developments affecting investor sentiment.
Jonathan Lim received an elite international legal education across prominent academic institutions. He completed his foundational legal training at the National University of Singapore Faculty of Law, where he earned his primary law degree.
Erasca, Inc. trades on the Nasdaq stock exchange under the ticker symbol ERAS at approximately $18.15 per share.
Erasca, Inc. officially completed its initial public offering and began trading its shares on the NASDAQ Global Select Market under the ticker symbol ERAS on July 16, 2021.
Erasca reported a net loss and a wider-than-expected loss per share of sixty cents for the first quarter, reflecting intensive capital investments and rising research and development expenditures as the clinical-stage oncology enterprise advanced its...
Erasca (ERAS) is currently classified by many financial analysts as a "Buy," reflecting professional optimism regarding its potential in the precision oncology market.
Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with cancer, is based in San Diego, California.
Operating as a specialized precision oncology enterprise, Erasca researches and develops innovative therapeutic drug candidates targeted specifically at oncogenic drivers within the mitogen-activated protein kinase signaling pathway.
The consensus among Wall Street analysts covering Erasca (ERAS) is currently a "Buy.